CLINICAL_TRIALS
research
· 2026-04-01
Clinical Trial Update: A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC [Phase 1, Phase 2]
Summary
A Phase 1/2 clinical trial evaluating 161Tb-RAD402 for castration-resistant prostate cancer is currently recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Radiopharm Theranostics, Ltd | Conditions: Castration-resistant Prostate Cancer | Phase 1, Phase 2 | Status: RECRUITING